Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C3808940
Disease: LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 5
LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 5 		0.600 GermlineCausalMutation disease ORPHANET Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. 20049731 2009
CUI: C3808940
Disease: LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 5
LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 5 		0.600 Biomarker disease GENOMICS_ENGLAND Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. 20049731 2009
CUI: C3808940
Disease: LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 5
LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 5 		0.600 CausalMutation disease CLINVAR
CUI: C0271694
Disease: Familial partial lipodystrophy
Familial partial lipodystrophy 		0.310 Biomarker disease BEFREE CIDEC is the disease gene for autosomal recessive, FPL and LMNA and ZMPSTE24 for autosomal recessive, mandibuloacral dysplasia-associated lipodystrophy. 21865368 2011
CUI: C0271694
Disease: Familial partial lipodystrophy
Familial partial lipodystrophy 		0.310 Biomarker disease CTD_human
CUI: C0162820
Disease: Dermatitis, Allergic Contact
Dermatitis, Allergic Contact 		0.300 Biomarker disease CTD_human Microarray analyses in dendritic cells reveal potential biomarkers for chemical-induced skin sensitization. 17374397 2007
CUI: C1720859
Disease: Familial Partial Lipodystrophy, Type 1
Familial Partial Lipodystrophy, Type 1 		0.300 Biomarker disease CTD_human
CUI: C1720860
Disease: Familial Partial Lipodystrophy, Type 2
Familial Partial Lipodystrophy, Type 2 		0.300 Biomarker disease CTD_human
CUI: C1720861
Disease: Familial Partial Lipodystrophy, Type 3
Familial Partial Lipodystrophy, Type 3 		0.300 Biomarker disease CTD_human
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.170 AlteredExpression disease BEFREE Fsp27 is highly expressed in adipose tissue and fatty liver. 31564684 2020
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.170 Biomarker disease BEFREE Plasticity of histone modifications around Cidea and Cidec genes with secondary bile in the amelioration of developmentally-programmed hepatic steatosis. 31745102 2019
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.170 AlteredExpression disease BEFREE In contrast, CIDEA expression decreased, but FSP27-β expression strongly increased in a dietary mouse model of steatohepatitis. 31097771 2019
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.170 AlteredExpression disease BEFREE Fat-specific protein 27 (FSP27) is highly expressed in the fatty liver of genetically obese ob/ob mice and promotes hepatic triglyceride (TG) accumulation. 29454584 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.170 Biomarker disease BEFREE Data show that ASO-Fsp27 and fenofibrate synergize to promote resistance to diet-induced obesity and hypertriglyceridemia and to reverse hepatic steatosis, inflammation, oxidative stress, and fibrosis. 28874443 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.170 AlteredExpression disease BEFREE Fsp27 is highly expressed in adipose tissue as well as the fatty liver of ob/ob mice. 28566630 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.170 AlteredExpression disease BEFREE We attributed these effects to ceramide that can suppress peroxisome proliferator-activated receptor γ2, thus reducing the expression of Cd36 and Fsp27 and reducing liver steatosis. 23640498 2013
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.170 Biomarker disease HPO
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.160 AlteredExpression disease BEFREE Fsp27 is highly expressed in adipose tissue and fatty liver. 31564684 2020
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.160 Biomarker disease BEFREE Plasticity of histone modifications around Cidea and Cidec genes with secondary bile in the amelioration of developmentally-programmed hepatic steatosis. 31745102 2019
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.160 AlteredExpression disease BEFREE Fat-specific protein 27 (FSP27) is highly expressed in the fatty liver of genetically obese ob/ob mice and promotes hepatic triglyceride (TG) accumulation. 29454584 2018
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.160 AlteredExpression disease BEFREE Fsp27 is highly expressed in adipose tissue as well as the fatty liver of ob/ob mice. 28566630 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.160 Biomarker disease BEFREE Data show that ASO-Fsp27 and fenofibrate synergize to promote resistance to diet-induced obesity and hypertriglyceridemia and to reverse hepatic steatosis, inflammation, oxidative stress, and fibrosis. 28874443 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.160 AlteredExpression disease BEFREE We attributed these effects to ceramide that can suppress peroxisome proliferator-activated receptor γ2, thus reducing the expression of Cd36 and Fsp27 and reducing liver steatosis. 23640498 2013
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.160 Biomarker disease HPO
CUI: C0020557
Disease: Hypertriglyceridemia
Hypertriglyceridemia 		0.110 Biomarker phenotype BEFREE Data show that ASO-Fsp27 and fenofibrate synergize to promote resistance to diet-induced obesity and hypertriglyceridemia and to reverse hepatic steatosis, inflammation, oxidative stress, and fibrosis. 28874443 2017